2)、動脈血二氧化碳分壓(PaCO2)、肺動脈壓(PAP)、動脈血氧飽和度(SaO2)、血清內(nèi)皮素(ET-1)、缺氧誘導(dǎo)因子(HIF-1α)、一氧化氮(NO)、促紅細胞生成素(EPO)、Ca2+的變化。結(jié)果 治療后,對照組和治療組總有效率分別為82.22%、95.56%,兩組總有效率比較差異具有統(tǒng)計學(xué)意義(P < 0.05)。兩組PaO2、SaO2、NO均較治療前顯著升高,PaCO2、PAP、EPO、HIF-1、ET-1較治療前顯著降低,同組治療前后差異有統(tǒng)計學(xué)意義(P < 0.01);治療組這些觀察指標的改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計學(xué)意義(P < 0.05)。兩組Ca2+均較治療前顯著升高(P < 0.05),但兩組比較差異無統(tǒng)計學(xué)意義。結(jié)論 多巴胺聯(lián)合西地那非治療新生兒肺動脈高壓具有較好的臨床療效,可顯著調(diào)節(jié)缺氧相關(guān)因子水平,值得臨床推廣應(yīng)用。;Objective To investigate the effect of dopamine combined with sildenafil in treatment of neonates with pulmonary arterial hypertension. Methods Patients (90 cases) with pulmonary arterial hypertension in Tianjin Xiqing Hospital from June 2011 to November 2014 were randomly divided into control and treatment groups, and each group had 45 cases. The patients in the control group were po or nasal feeding administered with Sildenafil Citrate Tablets, 0.5~1.0 mg/(kg·time), one time/6 h. The patients in the treatment group were iv administered with Dopamine Hydrochloride Injection on the basis of control group, 5 μg/(kg·min), continuous intravenous drip infusion pump. Two groups were treated for 3 d. After treatment, the efficacy was evaluated, and the changes of PaO2, PaCO2, PAP, SaO2, ET-1, HIF-1α, NO, EPO, and Ca2+ in two groups were compared. Results The efficacies in the control and treatment groups were 82.22% and 95.56%, respectively, and there were differences between two groups (P < 0.05). After treatment, PaO2, SaO2, and NO in two groups were significantly increased, while PaCO2, PAP, EPO, HIF-1, and ET-1 were significantly reduced, and the difference was statistically significant in the same group (P < 0.01). And these indicators in treatment group improved better than those in the control group, with significant difference between two groups (P < 0.05). Ca2+ in two groups were significantly increased (P < 0.05), and there was no statistically significant difference between two groups. Conclusion Dopamine combined with sildenafil has the good clinical effect in treatment of neonates with pulmonary arterial hypertension, and can adjust hypoxia correlated factors levels, which is worth clinical promotion"/> 2;PaCO2;PAP;SaO2;ET-1;HIF-1α;NO;EPO"/>